The Alliance to Protect Medical Innovation in a recent article says drug pricing proposals circulating in the government put innovation at risk.
APM says the Food and Drug Administration approved 59 drugs last year, 43 of which belonged to a category for “speedy review for either treating an unmet need or being deemed a breakthrough therapy because they are expected to significantly improve on existing options.
However, citing an opinion article published on STAT, APM says the proposals could be detrimental to innovation “because policymakers misunderstand ‘the nature of early-stage drug development and the mobility of investment capital.'”
To read more on APBM’s website, click here.
